Vitamin K2 for Cellular Health
Beyond its coagulation and calcium-handling roles, broader cellular benefits of K2 are speculative.
Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- 180 mcg/day of MK-7 with food; cellular health is not a measurable endpoint and has not been tested
- Expected timeframe
- Not established
Protocol
- form
- MK-7 (menaquinone-7) with a fat-containing meal
- duration
- Not applicable - no cellular health endpoint exists
- co factor
- Evidence is insufficient because the outcome is not defined. Vitamin K2 has well-characterised specific functions: gamma-carboxylation of osteocalcin in bone, matrix Gla protein in vasculature and Gas6 in various tissues, plus a role in mitochondrial electron transport demonstrated in Drosophila by Vos and colleagues, which generated interest in cellular energetics. None of this constitutes evidence for cellular health as an outcome, which has no clinical definition, no validated measurement and no trial endpoint. The demonstrated benefits of K2 are vascular calcification and bone carboxylation.
- titration
- Not applicable for this outcome; 180 mcg/day of MK-7 is the standard studied dose
- starting dose
- Not established for this outcome. General K2 trials used 180 mcg/day of MK-7 or 45 mg/day of MK-4
Evidence
What the studies say
No studies are yet linked to both Vitamin K2 and Cellular Health.
Safety
Caveats
Cellular health is a marketing category rather than a health outcome - it cannot be measured, has no trial endpoint, and no supplement can be shown to improve it. Vitamin K2 has real and specific functions worth understanding on their own terms: carboxylating osteocalcin for bone matrix binding and matrix Gla protein for inhibiting vascular calcification, with the best trial evidence in arterial stiffness over three years. The mitochondrial electron carrier finding comes from Drosophila research and has not been shown relevant to human cellular energetics. Safety of vitamin K2: the critical interaction is with warfarin and other vitamin K antagonists, which it directly opposes, risking dangerous loss of anticoagulation - do not combine without anticoagulation clinic advice. It does not interact with DOACs. No tolerable upper intake level has been set and it is generally well tolerated, though long-term high-dose data are limited. In pregnancy and breastfeeding, high-dose supplementation is not recommended for lack of data. Note that newborns receive vitamin K prophylaxis at birth, which is a separate and important medical intervention.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.